Summit Therapeutics (SMMT) Accumulated Expenses (2019 - 2026)

Summit Therapeutics (SMMT) has 8 years of Accumulated Expenses data on file, last reported at $65.1 million in Q2 2026.

• Quarterly Accumulated Expenses rose 148.8% year-over-year to $65.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $65.1 million (up 148.8% YoY) and the FY2025 annual result came in at $32.1 million, up 64.16% from the prior year.
• Accumulated Expenses rose to $65.1 million in Q2 2026, from $44.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $65.1 million in Q2 2026 to a low of $3.7 million in Q3 2023.
• A 5-year average of $18.7 million and a median of $12.4 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses slumped 67.2% — and 2024, when it soared 405.67%.
• Tracing SMMT's Accumulated Expenses over 5 years: stood at $10.7 million in 2022, then slipped by 17.64% to $8.8 million in 2023, then jumped by 122.63% to $19.6 million in 2024, then jumped by 64.16% to $32.1 million in 2025, then surged by 102.66% to $65.1 million in 2026.
• The last three Accumulated Expenses figures came in at $65.1 million (Q2 2026), $44.3 million (Q1 2026), and $32.1 million (Q4 2025), per Business Quant data.